Sky Medical Technology’s Post

Our recently published randomised self-controlled trial (RCT) compared the rate of healing of chronic VLUs with and without the geko™ device, with each patient acting as their own control. The study measured the rate of healing using wound margin advance (WMA) and percentage area reduction (PAR). The results show that the addition of the geko™ device to standard of care (SoC) more than doubled the rate of healing of VLUs compared with SoC alone. Click here to learn more: https://lnkd.in/gz-a2BiX

Our recently published randomised self-controlled trial (RCT) compared the rate of healing of chronic VLUs with and without the geko™ device, with each patient acting as their own control. The study measured the rate of healing using wound margin advance (WMA) and percentage area reduction (PAR). The results show that the addition of the geko™ device to standard of care (SoC) more than doubled the rate of healing of VLUs compared with SoC alone. Click here to learn more: https://lnkd.in/gz-a2BiX

Why are endovascular tools so often undersized? Hear Drs. Eric Secemsky and Michael Siah speak about this important topic and learn about its clinical implications. Watch the three-part series on VuMedi: https://lnkd.in/g_6KuPXs US Rx only. See Important Safety Information: http://bit.ly/3iEq7fC

RESHAPE HF2 is a randomised study comparing the use of MitraClip in addition to standard care Vs standard care alone in patients with heart failure and secondary MR There is anticipation around how RESHAPE HF2's results will be interpreted in the context of the existing evidence The trial's outcome could either reinforce or challenge the conclusions drawn from COAPT and MITRA FR, particularly regarding the use of TEER for secondary MR in heart failure patients Discussed by Nicolas Van Mieghem and Joost Daemen

Believe it or not... Clinical data from over 500 patients undergoing RF cardiac ablation revealed a 14% absolute increase in freedom from atrial arrhythmia at one year with ensoETM®, compared to traditional LET monitoring. Curious about the reasons behind this improvement? Dive into the evidence and explore the mechanisms in the full study: https://lnkd.in/ebMz54Sc #EPlab #ensoETM #Epeeps

Don't miss the late-breaker Self-Expanding Versus Balloon-Expandable Transcatheter Aortic Valve Replacement in Patients with Small Aortic Annuli: Additional Outcomes from the SMART Trial on May 3 at #SCAI2024. https://bit.ly/3WxK63E

Mark your calendar! The Option trial compares the safety and effectiveness of the WATCHMAN FLX device with oral anticoagulation for stroke prevention post-ablation. #LAAC #WatchmanFLX #BSCI

Spray Cryotherapy for Benign Large Airway Stenosis A Multicenter Retrospective Cohort Study of Safety and Practice Patterns   Recently published in JOBIP – Learn how trūFreeze® Spray Cryotherapy can impact your patients as an adjunct therapy for benign large airway stenosis: https://bit.ly/48FMx6O

April 10th's announcement that Bosch and Randox Laboratories will work together on a new platform for the diagnosis of sepsis is undoubtedly good news for both patients and clinicians, who desperately need new tools to solve this critical healthcare issue. Moreover, the companies' combined €150m of spending is also proof that sepsis is still a strong area for investment. And while Bosch's BioMEMs platform by itself is impressive, we believe the addition of Cellectric's electrodynamics platform would be a perfect synergy: by vastly reducing sample complexity, consistent, higher-quality results can be obtained. Discover our sepsis solution: https://lnkd.in/gHKMQVRx 

Key point: A phase 3, open-label extension trial of adjunctive LCM was carried out in patients (aged ≥4 years) with IGE. https://lnkd.in/gF3-USw7